| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
SUNPHARMA Stock Overview
Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations and active pharmaceutical ingredients (APIs) in India and internationally.
Sun Pharmaceutical Industries Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹808.75 |
| 52 Week High | ₹871.00 |
| 52 Week Low | ₹550.40 |
| Beta | 0.48 |
| 1 Month Change | 2.97% |
| 3 Month Change | -0.55% |
| 1 Year Change | 40.60% |
| 3 Year Change | 91.47% |
| 5 Year Change | 26.27% |
| Change since IPO | 39,683.11% |
Recent News & Updates
Should You Be Adding Sun Pharmaceutical Industries (NSE:SUNPHARMA) To Your Watchlist Today?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Estimating The Intrinsic Value Of Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA)
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Sun Pharmaceutical...
Sun Pharmaceutical Industries (NSE:SUNPHARMA) Seems To Use Debt Rather Sparingly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Shareholder Returns
| SUNPHARMA | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -5.9% | -4.5% | -3.4% |
| 1Y | 40.6% | 8.8% | 32.6% |
Return vs Industry: SUNPHARMA exceeded the Indian Pharmaceuticals industry which returned 8.8% over the past year.
Return vs Market: SUNPHARMA exceeded the Indian Market which returned 32.6% over the past year.
Price Volatility
| SUNPHARMA volatility | |
|---|---|
| SUNPHARMA Average Weekly Movement | 3.4% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in IN Market | 9.9% |
| 10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: SUNPHARMA is less volatile than 75% of Indian stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: SUNPHARMA's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 37,000 | Dilip Shanghvi | https://www.sunpharma.com |
Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers formulations in various therapeutic areas, including central nervous system, dermatology, cardiology, oncology and ophthalmic, neuro-psychiatry, gastroenterology, anti-infectives, diabetology, pain/analgesics, vitamins/minerals/nutrients, respiratory, gynaecology, urology, ophthalmology, orthopaedic, nephrology, dental, and other areas. It also provides APIs for anti-cancers, peptides, steroids, sex hormones, and controlled substances, as well as over-the-counter products.
Sun Pharmaceutical Industries Fundamentals Summary
| SUNPHARMA fundamental statistics | |
|---|---|
| Market Cap | ₹1.94t |
| Earnings (TTM) | ₹62.38b |
| Revenue (TTM) | ₹367.04b |
31.1x
P/E Ratio5.3x
P/S RatioIs SUNPHARMA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SUNPHARMA income statement (TTM) | |
|---|---|
| Revenue | ₹367.04b |
| Cost of Revenue | ₹102.74b |
| Gross Profit | ₹264.31b |
| Expenses | ₹201.93b |
| Earnings | ₹62.38b |
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
Jan 31, 2022
| Earnings per share (EPS) | 26.00 |
| Gross Margin | 72.01% |
| Net Profit Margin | 16.99% |
| Debt/Equity Ratio | 3.4% |
How did SUNPHARMA perform over the long term?
See historical performance and comparisonDividends
0.9%
Current Dividend Yield30%
Payout RatioValuation
Is Sun Pharmaceutical Industries undervalued compared to its fair value and its price relative to the market?
31.11x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: SUNPHARMA (₹808.75) is trading above our estimate of fair value (₹697.2)
Significantly Below Fair Value: SUNPHARMA is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: SUNPHARMA is poor value based on its PE Ratio (31.1x) compared to the Indian Pharmaceuticals industry average (25.7x).
PE vs Market: SUNPHARMA is poor value based on its PE Ratio (31.1x) compared to the Indian market (23x).
Price to Earnings Growth Ratio
PEG Ratio: SUNPHARMA is poor value based on its PEG Ratio (2x)
Price to Book Ratio
PB vs Industry: SUNPHARMA is overvalued based on its PB Ratio (3.9x) compared to the IN Pharmaceuticals industry average (3.1x).
Future Growth
How is Sun Pharmaceutical Industries forecast to perform in the next 1 to 3 years based on estimates from 31 analysts?
15.8%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SUNPHARMA's forecast earnings growth (15.8% per year) is above the savings rate (6.7%).
Earnings vs Market: SUNPHARMA's earnings (15.8% per year) are forecast to grow slower than the Indian market (21.3% per year).
High Growth Earnings: SUNPHARMA's earnings are forecast to grow, but not significantly.
Revenue vs Market: SUNPHARMA's revenue (9.9% per year) is forecast to grow slower than the Indian market (12.9% per year).
High Growth Revenue: SUNPHARMA's revenue (9.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SUNPHARMA's Return on Equity is forecast to be low in 3 years time (14.8%).
Past Performance
How has Sun Pharmaceutical Industries performed over the past 5 years?
-10.4%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SUNPHARMA has high quality earnings.
Growing Profit Margin: SUNPHARMA's current net profit margins (17%) are higher than last year (4.5%).
Past Earnings Growth Analysis
Earnings Trend: SUNPHARMA's earnings have declined by 10.4% per year over the past 5 years.
Accelerating Growth: SUNPHARMA's earnings growth over the past year (324.2%) exceeds its 5-year average (-10.4% per year).
Earnings vs Industry: SUNPHARMA earnings growth over the past year (324.2%) exceeded the Pharmaceuticals industry 29.7%.
Return on Equity
High ROE: SUNPHARMA's Return on Equity (11.9%) is considered low.
Financial Health
How is Sun Pharmaceutical Industries's financial position?
Financial Position Analysis
Short Term Liabilities: SUNPHARMA's short term assets (₹320.8B) exceed its short term liabilities (₹148.1B).
Long Term Liabilities: SUNPHARMA's short term assets (₹320.8B) exceed its long term liabilities (₹17.8B).
Debt to Equity History and Analysis
Debt Level: SUNPHARMA has more cash than its total debt.
Reducing Debt: SUNPHARMA's debt to equity ratio has reduced from 20.3% to 3.4% over the past 5 years.
Debt Coverage: SUNPHARMA's debt is well covered by operating cash flow (462.7%).
Interest Coverage: SUNPHARMA earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Dividend
What is Sun Pharmaceutical Industries's current dividend yield, its reliability and sustainability?
0.93%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: SUNPHARMA's dividend (0.93%) is higher than the bottom 25% of dividend payers in the Indian market (0.3%).
High Dividend: SUNPHARMA's dividend (0.93%) is low compared to the top 25% of dividend payers in the Indian market (1.34%).
Stability and Growth of Payments
Stable Dividend: SUNPHARMA's dividend payments have been volatile in the past 10 years.
Growing Dividend: SUNPHARMA's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (29.8%), SUNPHARMA's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: SUNPHARMA's dividends in 3 years are forecast to be well covered by earnings (18.1% payout ratio).
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
7.3yrs
Average board tenure
CEO
Dilip Shanghvi (66 yo)
no data
Tenure
₹46,052,839
Compensation
Mr. Dilip Shantilal Shanghvi has been the Chairman of Sun Pharma Advanced Research Company Limited since March 1, 2012 and served as its Managing Director since March 1, 2012 until May 25, 2021 . Mr. Shang...
CEO Compensation Analysis
Compensation vs Market: Dilip's total compensation ($USD619.65K) is below average for companies of similar size in the Indian market ($USD1.20M).
Compensation vs Earnings: Dilip's compensation has been consistent with company performance over the past year.
Board Members
Experienced Board: SUNPHARMA's board of directors are considered experienced (7.3 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: SUNPHARMA insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Sun Pharmaceutical Industries Limited's employee growth, exchange listings and data sources
Key Information
- Name: Sun Pharmaceutical Industries Limited
- Ticker: SUNPHARMA
- Exchange: NSEI
- Founded: 1983
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: ₹1.940t
- Shares outstanding: 2.40b
- Website: https://www.sunpharma.com
Number of Employees
Location
- Sun Pharmaceutical Industries Limited
- Sun House
- Plot No. 201 B/1
- Mumbai
- Maharashtra
- 400063
- India
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/01/23 12:05 |
| End of Day Share Price | 2022/01/21 00:00 |
| Earnings | 2021/09/30 |
| Annual Earnings | 2021/03/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.